DR. PAUL JAN DEUTSCH, M.D.
Osteopathic Medicine at Maybury Hill Rd, Princeton, NJ

6180634, Jan 30, 2001

Nov 13, 1998

9/191895

Joseph P. Vacca - Telford PA
Jiunn H. Lin - Ambler PA
Kuang C. Yeh - Lansdale PA
Paul J. Deutsch - Princeton NJ
William D. Ju - Morris Township NJ
Jeffrey A. Chodakewitz - Lower Gwynedd PA

Merck & Co., Inc. - Rahway NJ

A61K 31495, A61K 3150, A61K 3134

51425411

The combination of the HIV protease inhibitor Compound A and one or more nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, or protease inhibitors is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of AIDS, either as compounds, pharmaceutically acceptable salts or esters, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

2009024, Oct 1, 2009

May 20, 2008

12/154087

Stanley R. Frankel - Yardley PA, US
Paul J. Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US
Bernard Fine - Menlo Park CA, US

A61K 31/497, A61P 35/00

51425505

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

2008022, Sep 11, 2008

May 2, 2008

12/150999

Paul Bunn - Evergreen CO, US
Samir Witta - Greenwood Village CO, US
Victoria M. Richon - Wellesley MA, US
Stanley R. Frankel - Yardley PA, US
Paul J. Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US

A61K 31/517, A61P 35/00

5142664

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

2007019, Aug 23, 2007

Nov 3, 2006

11/592443

Paul Bunn - Evergreen CO, US
Samir Witta - Greenwoodvillage CO, US
Victoria Richon - Wellesley MA, US
Stanley Frankel - Yardley PA, US
Paul Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US

A61K 31/517, A61K 31/19

514266400, 514575000

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

2007019, Aug 23, 2007

Nov 3, 2006

11/592528

Stanley Frankel - Yardley PA, US
Paul Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US
Bernard Fine - Menlo Park CA, US

A61K 31/69, A61K 31/19

514064000, 514575000

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.